How much does a box of Daprodustat currently cost, combined with the real prices from different channels at home and abroad?

Daprodustat is an oral small molecule HIF-PH inhibitor mainly used to treat patients with anemia associated with chronic kidney disease. It improves anemia symptoms by stabilizing hypoxia-inducible factor (HIF), promoting endogenous erythropoietin production and regulating iron metabolism. Clinically, dapoprimostat is viewed as an innovative oral option for erythropoietin replacement therapy, particularly for patients with chronic kidney disease who require long-term anemia management.

In the domestic market, the original drug of daprostat has not yet been launched and has not been included in medical insurance, so the price information is not yet clear. Patients are currently unable to directly purchase the domestic pharmacy version through formal channels. If they need to use the drug, they can only rely on overseas channels or clinical trials, which also limits its accessibility in the country. Clinicians need to fully consider the feasibility of drug acquisition and economic factors when planning treatment.

In overseas markets, the original drug of dapoxostat is already available. Common specifications include 1mg30 tablets and 2mg30 tablets, etc., each box sells for approximately 100 to 500 US dollars. Prices may fluctuate due to exchange rates and purchasing channels. Overseas original drugs are mainly intended for patients with chronic kidney disease and anemia, and are used for long-term oral maintenance treatment. Their prices are relatively high, and reasonable planning needs to be carried out based on the patient's economic conditions and medication cycle.

In addition, generic drugs of daprostat have appeared in overseas markets, and the drug ingredients are basically the same as the original drug. Taking Lucius Pharmaceuticals of Laos as an example, its specifications are 1mg*100 tablets, and each box sells for about more than 400 yuan (the price may fluctuate due to exchange rates). The emergence of generic drugs has provided patients with more economical options and increased drug accessibility. In actual medication use, patients and clinicians should make reasonable choices based on drug sources, dosage requirements and cost factors to ensure the continuity and safety of long-term anemia management.

Keyword tags: Daprostat, HIF-PHinhibitor, anemia in chronic kidney disease, price, generic drugs

Reference materials:https://www.drugs.com/international/daprodustat.html